1st Edition

Chronic Myeloproliferative Disorders

Edited By Tariq Mughal, John M. Goldman Copyright 2013

    With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients.

    This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.

    Part I - Bcr/Abl positive Chronic Myeloproliferative Disorders  1. History  2. Cytogenetics & Molecular Biology  3. Risk Stratification Models  4. Clinical Aspects  5. Current Treatment Options  6. Emerging treatment Options  7. Transplant Options  8. Monitoring response to therapy  9. Immunotherapy  10. Furture Directions Part II - Bcr/Abl negative Chronic Myeloproliferative Disorders  1. History  2. Ph-negative Chronic Myelproliferative Leukemias  3. Systemic mastocytosis  4. Polycythemia vera  5. Idiopathic myelofibrosis  6. Essential thrombocythemia  7. Transplant Options  8. Therapeutic strategies

    Biography

    TARIQ I MUGHAL is Professor of Medicine and Haematology/Oncology at the University of Texas Southwestern Medical School, Dallas, USA and Consultant Haematologist at Guy’s & St Thomas’ Hospitals, London UK

    JOHN M. GOLDMAN is Professor of Haematology at Imperial College London, Hammersmith Hospital, London, UK.